PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 1
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED 
STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY,AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN 
HEALTHY ADULTS 65 TO 85 YEARS OF AGE
Investigational Product Number: PF-06425090
Investigational Product Name: Clostridium difficile Vaccine
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:Not Applicable (N/A)
Protocol Number: B5091008
Phase: 3
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes and Rational e
Protocol A mendment 1 08Nov 2018 Clostridium difficile Disease Background, 
Section 1.2.1, has been updated to reflect 
the most recent therap y recommendations 
for the treatment of Clostridium difficile
infection (CDI), and a reference was 
added.
The secondary  endpoints such as 
geometric mean fold rises (GMFRs) for 
neutralizing antibod y were not intended to 
explore any  additional aspects of the 
vaccine lot comparisons bey ond those 
assessed for the primar y objective.  
Therefore, the secondary  objectives and 
endpoints 
were changed to exploratory  
objectives and endpoints in Sections 2and
9.2.3.
To ensure that subjects continue to mee t 
eligibility  requirements at Visit 5, the 
Schedule of Activities and Procedures 
(Section 6.1.5) were updated.
Medical Device Complaint Reporting 
Requirements, 
Section 8.5, has been 
updated to incorporate the Protocol 
Administrative Change Letter (PACL) ,
dated 18 April 2018, thatprevent s
accidental unblinding .
Original protocol 08Jan2018 N/A
This amendment incorporates all r evisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics committees 
(ECs).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................6
APPENDI CES ...........................................................................................................................6
PROTOCOL  SUMMARY .........................................................................................................7
SCHEDUL E OF ACTIVITI ES..................................................................................................9
1. INTRODUCTION ...............................................................................................................10
1.1. Mechanism of Action/I ndication .............................................................................10
1.2. Background and Rationale
......................................................................................10
1.2.1. Clostridium difficile Disease Background ..................................................10
1.2.2. Clostridium difficile Vaccine Development Rationale ...............................11
1.2.3. Clostridium difficile Vaccine Candidate .....................................................12
1.2.3.1. Nonclinical Development ..........................................................12
1.2.3.2. Clinical Development ................................................................12
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................14
3. STUDY DESIGN .................................................................................................................14
3.1. Approximate Number of Subjects ...........................................................................14
3.2. Approximate Duration of Subject Participation
......................................................15
3.3. Appr oximate Duration of the Study ........................................................................15
4. SUBJECT ELIGIBILI TY CRI TERIA .................................................................................15
4.1. I nclusion Criteria .....................................................................................................15
4.2. Exclusion Criteria ....................................................................................................16
4.3. Criteria for Temporarily  Delay ing Vaccine Administration ...................................17
4.4. Lifesty le Requirements ...........................................................................................18
4.4.1. Contraception ..............................................................................................18
4.5. Sponsor’s Qualified Medical Personnel ..................................................................19
5. INVESTIGAT IONAL P RODUCTS ...................................................................................19
5.1. Allocation to I nvestigational Product ......................................................................19
5.2. Blinding of Si te Personnel .......................................................................................20
5.3. Blinding of the Sponsor
...........................................................................................20
5.4.Breaking the Blind ..................................................................................................20
5.5. Subject Compliance .................................................................................................21
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 45.6. Vaccine Supplies .....................................................................................................21
5.6.1. Formulation and Packaging ........................................................................21
5.6.1.1. Clostridium difficile Vaccine ....................................................21
5.6.1.2. Placebo ......................................................................................21
5.6.2. Preparation and Dispensi ng
........................................................................21
5.6.3. Administration ............................................................................................21
5.7. I nvestigational Product Storage ..............................................................................22
5.8. I nvestigational Product Accountabilit y
...................................................................23
5.8.1. Destruction of Investigational Product Supplies
........................................23
5.9. Concomitant Medication(s) .....................................................................................23
5.9.1. Recording Concomitant Vaccinations and Medications
.............................23
5.9.2. Prohibited Concomitant Vaccinations and Me dications .............................23
5.9.3. Permitted Concomitant Medications
..........................................................24
6. STUDY PROCEDURES
.....................................................................................................24
6.1. Study  Period ............................................................................................................24
6.1.1. Visit 1: Month 0 
–Vaccination 1 (Day  1) ..................................................24
6.1.2. Visit 2: Month 1 
–Vaccination 2 (28 to 42 Day s After Visit 1) ................26
6.1.3. Visit 3: Month 2 (28 to 42 Day s After Visit 2) ...........................................27
6.1.4. Visit 4: Month 6 
–Vaccination 3 (140 to 168 Day s After Visit 2) ............27
6.1.5. Visit 5: Month 7 (28 to 42 Day s After Visit 4) ...........................................29
6.1.6. Unscheduled Visit for a Gra
de 3 or Suspected Grade 4 Reaction..............29
6.2. Subject Withdrawal .................................................................................................29
7. ASSESSMENTS ..................................................................................................................30
7.1.Safet y Assessments .................................................................................................30
7.1.1. Electronic Diary ..........................................................................................31
7.1.1.1. Grading Scales ...........................................................................31
7.1.1.2. L ocal Reactions .........................................................................31
7.1.1.3. Sy stemic Events ........................................................................32
7.1.1.4. Fever ..........................................................................................33
7.2. I mmunogenicit y Assessments .................................................................................33
7.3. Biological Samples ..................................................................................................34
8. ADVERSE EVENT REP ORTI NG......................................................................................34
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 58.1. Requirements...........................................................................................................34
8.1.1. Additional Details on Recording Adverse Events on the CRF...................358.1.2. Eliciting Adverse Event Information..........................................................358.1.3. Withdrawal From the Study Due to Adverse Events (see also the 
Subject Withdrawal section)............................................................................36
8.1.4. Time Period for Collecting AE/SAE Information......................................36
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................368.1.4.2. Recording Nonserious AEs and SAEs on the CRF...................36
8.1.5. Causality Assessment .................................................................................368.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................37
8.2. Definitions............................................................................................................... 37
8.2.1. Adverse Events ...........................................................................................378.2.2. Abnormal Test Findings .............................................................................388.2.3. Serious Adverse Events ..............................................................................388.2.4. Hospitalization............................................................................................39
8.3. Severity Assessment................................................................................................418.4. Special Situations ....................................................................................................41
8.4.1. Protocol-Specified Serious Adverse Events ...............................................418.4.2. Potential Cases of Drug-Induced Liver Injury............................................418.4.3. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................43
8.4.3.1. Exposure During Pregnancy......................................................438.4.3.2. Exposure During Breastfeeding ................................................448.4.3.3. Occupational Exposure .............................................................44
8.4.4. Medication Errors .......................................................................................45
8.4.4.1. Medication Errors......................................................................45
8.5. Medical Device Complaint Reporting Requirements .............................................46
9. DATA ANALYSIS/STAT ISTICAL METHODS...............................................................46
9.1. Sample Size Determination.....................................................................................469.2. Immunogenicity Analysis .......................................................................................47
9.2.1. Immunogenicity Analysis Population.........................................................47
9.2.2. Analysis of the Primary Immunogenicity Endpoint ...................................48
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 69.3. Safet y Anal ysis........................................................................................................49
9.4. Analy sis Timing ......................................................................................................49
9.5. Data Monitoring Committee ...................................................................................49
10. QUALITY CONTROL  AND QUALITY ASSURANC E
.................................................50
11. DATA HANDLING AN
D RECORD KEEPING .............................................................51
11.1. Case Report Forms/Electronic Data Record .........................................................51
11.2. Record Retention ...................................................................................................51
12. ETHI CS..............................................................................................................................52
12.1. I nstitutional Review Board/Ethics Committee ......................................................52
12.2. Ethical Conduct of the Study ................................ ................................ ................ 52
12.3. Subject I nformation and Consent ..........................................................................52
12.4. Reporting of Safet y Issues and Serious Breaches o f the Protocol or ICH 
GCP ...........................................................................................................................53
13. DEFINITION OF EN D OF TRIAL ...................................................................................53
13.1. End of Trial in All Participating Countries ...........................................................53
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................53
15. PUBLICATION OF S TUDY RESUL TS..........................................................................53
15.1. Communication of Results by  Pfizer ....................................................................53
15.2. Publications by  Investigators ................................................................................54
16. REFERENCES ..................................................................................................................56
LIST OF TABLES
Table 1.
Local Reaction Grading Scale ..............................................................................32
Table 2. Systemic Event Grading Scale ..............................................................................32
Table 3. Scale for Fever ......................................................................................................33
Table 4. Power Anal ysis (Primary I mmunogenicit y Endpoint) .........................................47
APPENDICES
Appendix 1. Abbreviations ......................................................................................................61
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 7PROTOCOL SUMMARY
Indication
Pfizer’s investigational Clostridium difficile vaccine (PF -06425090) is a prophy lactic vaccine 
that is currentl y being investigated for the prevention of primary C difficile infection (CDI) in 
adults 50 y ears of age and older.
Objectives and Endpoints
Primary Immunogenicity Objective: Primary Immunogen icity Endpoint:
 To demonstrate that the immune responses induced by 
3 lots of C difficile vaccine are equivalent as measured 
by Cdifficile toxin A – and toxin B– specific 
neutralizing antibody levels 1 month after the third 
vaccination when administered in a 3-dose regimen to 
healthy adults 65 to 85 years of age. C difficile toxin A – and toxin B– specific neutralizing 
antibody levels for each lot, expressed as geometric 
mean concentrations (GMCs) (neutralization 
units/mL) at Month 7.
Primary Safety Objectiv e: Primary Safety Endpoints:
 To evaluate the safety of C difficile vaccine when 
administered in a 3 -dose regimen to healthy adults 65 
to 85 years of age, as measured by the number and 
percentage of subjects reporting local reactions and 
systemic events, adverse events, and serious adverse 
events. Local reactions (pain, erythema, and induration), as 
self-reported in electronic diaries (e -diaries) for up to 
7 days following each dose of investigational 
product .
 Systemic events (fever, vomiting, headache, fat igue, 
new or worsening muscle pain, and new or 
worsening joint pain), as self -reported in e -diaries for 
up to 7 days following each dose of investigational 
product .
 Nonserious adverse events from signing of the 
informed consent document (ICD) to 1 month af ter 
receipt of the third dose of investigational product.
 Serious adverse events from signing of the ICD to 
1 month after receipt of the third dose of 
investigational product .
Study Design
This is a Phase 3, placebo- controlled, randomized, observer -blind ed study  to evaluate the lot 
consistency , safety , tolerability , and immunogenicity  of an aluminum hy droxide 
(AlOH) -containing C difficile vaccine (200 g total toxoid) administered as a 3-dose regimen 
at Months 0, 1, and 6 in healthy  adults 65 to 85 years of age.
Subjects will be randomized into 1 of 4 groups in a 1:1:1:1 ratio (L ot 1: Lot 2: L ot 3: 
placebo).
Investigational Products
Clostridium difficile Vaccine
The investigational C difficile vaccine is toxoid based. C difficile toxin A and toxin B are 
inactivated b y a combination of genetic mutations and chemical treatments. The vaccine is 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 8provided as a sterile ly ophilized powder in a dosage strength of 200 g/dose (total for 
toxoids A and B) given at Month 0, Month 1, and Month 6. The vaccine will be 
reconstituted with AlOH diluent immediately  before use as instructed in the investigational 
product (IP) manual. The AlOH diluent is supplied as a 1 -mg aluminum/mL (as AlOH) 
liquid suspension.
Placebo
The placebo will consist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection, in a 0.5 -mL dose) and will be provided by  the sponsor to each study  site.
Statistical Methods
The study  sample size estimate is based on the study  primary  immunogenicity  objective to 
demonstrate lot -to-lot consistency , by evaluating the toxin A – and toxin B–specific 
neutralizing antibod
y in terms of GMCs, 1 month after the third vaccination (Month 7). A 
2-fold equivalence margin is used as the criterion; 263 evaluable subjects per lot will provide 
an ov erall 90% power to declare equivalence between all 6 comparisons for both toxin A and 
toxin B.
Assuming a maximum study  nonevaluable rate of 20%, a total of 1316 subjects need to be 
enrolled in the study  to meet the primary  objective, with a randomization ratio of 1:1:1:1 
(Lot1: Lot 2: Lot 3: placebo).
The primary  immunogenicity  objective of the lot -to-lot consistency  will be achieved if the 
2-sided 95% confidence intervals ( CIs) on the GMC ratios for all 6 comparisons are within 
the interval (0.5, 2), for both toxin A and toxin B.
All safet y and reactogenicity endpoints will be summarized as proportions of subjects with 
events by  vaccine group.  Additionally , exact 2- sided 95% CIs for proportions will be 
provided as applicable.
For immunogenicity  endpoints , GMCs and geometric mean fold rises (GMFRs) from 
baseline will be calculated by  vaccine group along with the 95% CI s for b
oth toxin A and 
toxin B.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 9SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and pr ocedures.  
Refer to the Study  Procedures and Assessments sections of the protocol for detailed 
information on each procedure and assessment required for compliance with the protocol.
The investigator may  schedule visits (unplanned visits) in addition to th ose listed on the 
schedule of activities table, in order to conduct evaluations or assessments required to protect 
the well -being of the subject.
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit Description Month 
0
(Vax 1)Month 1
(Vax 2)Month 2
(Phone 
Contact)Month 6
(Vax 3)Month 7
Visit Window (Days) 1 28-42 Days 
After Visit 128-42 Days 
After Visit 2140- 168 Days 
After Visit 228-42 Days 
After Visit 4
Informed consentaX
DemographyaX
Clinical assessment, including medical historyaX
Record nonstudy vaccinationsbX X X X X
Measure and record height and weightaX
Oral temperatureaX X X
Discuss contraceptive usebX X X X
Confirm eligibilitybX X X X X
Review temporary delay criteriaaX X X
RandomizationaX
Blood draw for immunogenicity assessmentbX Xc
Vaccination X X X
Postvaccination observation
(at least 30 minu tes) and AE assessmentX X X
Issue measuring device and thermometer, and 
provide instructions on their use, as requiredX X X
Assist the subject with downloading the app, 
or issue provisioned deviceX
Review e -diary completion requirements X X X
Record AEs /SAEs X X X X X
Telephone contact X
Review e -diary datad
Collect e -diary X
Abbreviations: e -diary = electronic diary; Vax = vaccination; = ongoing/continuous event.
a.Prior to vaccination.
b.Prior to vaccination, if at a vaccination visit.
c.Any AEs occurring up to 48 hours after blood draw  must be recorded on the case report form (CRF).
d. E- diary data review is ongoing during subject e -diary data- entry periods (7 d ays after each vaccination) via 
an internet -based portal.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 101.INTRODUCTION
1.1.Mechanism of Action/Indication
Pfizer’s investigational Clostridium difficile vaccine (PF -06425090) is a prophy lactic vaccine 
that is currentl y being investigated for the prevention of primary  C difficile infection (CDI) in 
adults 50 y ears of age and older.
1.2.Background and Rationale
1.2.1. Clostridium difficile Disease Background
C difficile , a gram -positive anaerobic, spore -forming bacillus, is the main cause of 
nosocomial infectious diarrhea in industrialized countries.1,2,3,4,5  It accounts for 20% to 30% 
of cases of antibiotic
-associated diarrhea and is the most commonly  recognized cause of 
infectious diarrhea in healthcare settings.6  C difficile is carried in approximately  3%of 
healthy  adults and approximately  16% to 35% of hospital inpatients; among the latter the rate 
increases with exposure to antibiotics.7  As many  as 50% or more of hospital patients 
colonized by  C difficile are asymptomatic carriers.6
C difficile can produce 3 toxins, toxin A (TcdA), toxin B (TcdB), and binary toxin.8  TcdA 
and TcdB are the principal virulence factors for CDI,9causing severe inflammation in the 
bowel.10
,11  The spectrum of CDI ranges from as ymptomatic colonization and mild 
self-limiting diarrhea, to more serious complications such as severe diarrhea, 
pseudomembranous colitis, toxic megacolon, intestinal perforation, and death.2,12
Indiv iduals with mild to moderate CDI may
 experience diarrhea 3 or more times a day  for 2 
or more day s, along with mild abdominal cramping and tenderness.  However, individuals 
with a severe infection may  experience watery  diarrhea 10 to 15 times a day , abdomin al 
cramping and pain that may  be severe, fever, blood or pus in the stool, nausea, dehy dration, 
loss of appetite, weight loss, swollen abdomen, kidney failure, and increased white blood cell 
count.13
The main ri sk factors for an initial episode of CDI are antibiotic therapy , prolonged 
hospitalization, and severe comorbidities.  Older adults (>65 y ears of age) are at an increased 
risk for CDI, particularly when exposed to healthcare settings.11,14,15,16,17  Although most 
patients experiencing a first episode of CDI respond well to standard antibiotic treatment, 
approximately  15% to 35% of patients suffer from at least 1 recurrence.11
,18,19Additional 
risk factors for recurrence include failure to mount an immune response to TcdA and/or 
TcdB and infection with a hy pervirulent strain.20,21
Increased incidence and severit y of the disease with associated complications, colectomy 
rates, and mortalit y have been observed over the last 10 to 20 y ears.22,23,24  In Europe, 
increased mortality
, prolonged length of hospital stay , and incremental cost of hospitalization 
in association with CDI  have been reported.25,26  A systematic review published in 2012 
reported 30
-day mortality  estimates in Europe ranging from 6.8% to 42%.26  In a surveillance 
study  conducted in the Unite d States, approximately  453,000 cases of CDI and 
approximately  29,000 deaths were reported in 2011.27  Based on data reported from acute 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 11care facilities, the cost of caring for patients experiencing CDI in the U nited States ranges 
from $1.1 to $4.8 billion annually .28,29
In the last decade, the numbers and severity  of C difficile iatrogenic outbreaks in hospitals 
and nursing homes have increased.27,28,30  Key factors in this escalation include emergence of 
hypervirulent pathogenic strains such as BI/NAP1/027,31,32,33increased use of antibiotics,34
improved detection methods, and increased exposure to spores in healthcare facilities.35
Metronidazole has been recommended as initial therapy  since the late 1990s
, but recent 
guidance issued b ytheInfectious Diseases Society of America (IDSA) recommends either 
vancom ycin or fidaxom icin as the first choice, and metronidazole should be used onl y if they 
are not available .6,21,36,37  Fidaxomicin has been developed more recently  and has been shown 
to be noninferior to vancomy cin for treatment of CDI .  In addition, treatment with 
fidaxomicin was associated wi th a significantl y lower rate of recurrence than was treatment 
with vancomy cin.19  European guidelines for treatment of CDI include fidaxomicin as an 
option for treatment of recurrence.21  Fecal transplantation has also been shown to be 
effective in some patients for the treatment of multiple recurrences of CDI.38,39  However, 
regulatory  oversight of this method remains in development,40and, therefore, a highly 
effective noninvasive treatment for complicated CDI does not exist.
To date, the onl y measures available to help prevent CDI  are behavioral ones such as 
encouraging appropriate use of antimicrobials, use of contact precautions, and cleaning and 
disinfection of equipment and the environment.41
1.2.2. Clostridium difficile Vaccine Development Ra tionale
It is well established that humoral immune responses to C difficile toxins play
 a significant 
role in preventing a more severe outcome or a recurrence of the disease in humans.  Several 
clinical studies suggest a correlation between high serum concentrations of antitoxin A and B 
immunoglobulin G (IgG) (as measured b y enz yme
-linked immunosorbent assay  [ELISA]) 
and protection from CDI or recurrence after primary  CDI.20,42,43,44  Preclinical studies have 
shown that active immunization with inactivated toxins (“toxoids”) and passive 
immunization with antitoxin antibodies protec t animals from lethal challenge.45
,46,47  A 
Phase 2 trial with monoclonal antibodies (mAbs) designed to neutralize TcdA a nd TcdB 
provides clinical evidence supporting a role for antitoxin antibodies in the prevention of CDI 
recurrences.48  Results of human studies showed that the rate of recurrence of CDI was 
significantl y lower w
hen the mAb against TcdB (bezlotoxumab) was administered, whether 
on its own or in combination with the mAb against TcdA (actoxumab), compared with 
placebo.49
To date, there is no approved vaccine to prevent primary  or recurrent CDI.  There are at least 
2 other vaccines in development that target C difficile toxins.  A toxoid- based vaccine 
adjuvanted with aluminum hy droxide (AlOH) has been evaluated in Phase 1 and 2 
studies,50,51,52,53and efficacy  is currently  being evaluated in a Phase 3 study .54  The other is a 
recombinant fusion protein comprising fragments of the receptor -binding domains of TcdA
and TcdB separated b y a 4–amino acid linker ;55this vaccine has been evaluated in a 
completed Phase 2study .56
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 12The increasing burden of CDI  on patients and on the healthcare s ystem demonstrates that 
prevention of CDI constitutes a significant unmet medical need.
1.2.3. Clostridium difficile Vaccine Candidate
Pfizer’s C difficile vaccine candidate consists of a 1:1 mixture of C difficile toxoids A and B.  
The toxoids were derived from native toxins by  genetic modification to decrease toxin 
activity , and chemical inactivation prior to final purification and formulation o f the drug 
substance.
1.2.3.1.
Nonclinical Development
In nonclinical experiments, Pfizer’s C difficile candidate vaccine was studied either alone or 
in combination with AlOH.  Using the standard hamster C difficile disease model, vaccine 
formulations with and with out AlOH demonstrated a survival benefit, providing at least 90% 
protection from a lethal challenge with C difficile spores in the immunized hamsters.  In 
addition, pooled sera obtained from hamsters immunized with the Cdifficile vaccine 
formulated with A lOH neutralized secreted toxins from C difficile isolates representing 
diverse ribot ypes/pulsed -field gel electrophoresis (PFGE) t ypes, including hypervirulent 
strains, and covering >67% and >70% of the circulating strains in the United States and 
Europe, respectivel y. In nonhuman primates, Pfizer’s toxoid vaccine formulations with and 
without AlOH induced robust neutralizing antitoxin antibody  responses to both TcdA and 
TcdB.  The nonclinical data generated b y Pfizer in rhesus macaques support the use of a 
3-dose regimen of the C difficile vaccine, with or without AlOH.
1.2.3.2. Clinical Development
The B5091001 first -in-human study  was a placebo -controlled, randomized, observer -
blinded 
Phase 1 study  that evaluated the safet y, tolerability, and immunogenicit y of Pf izer’s 
Cdifficile vaccine.  Three (3) antigen dose levels (50, 100, and 200 g) were assessed and 
administered either alone or in combination with AlOH at Months 0, 1, and 6 to healthy  
adults 50 to 85 y ears of age.57  Overall, the C difficile vaccine formulations and dose levels 
administered were generally  well tolerated.  Local reactions and s ystemic events were 
predominantly  mild to moderate, were more common in the 50 -to 64 -year age cohort, and 
comprised mos
tly injection site pain, headache, and fatigue.  Adverse events (AEs) were 
reported in all vaccine groups, with little difference in the number of subjects between the 
dose groups and the placebo group or between vaccine formulations.  I n subjects who 
received the vaccine formulations, both the toxin A –and toxin B –specific neutralizing 
antibody  geometric mean concentrations (GMCs) increased substantially  at 1 month after 
Dose 2 and after Dose 3 compared to baseline.  Potent antitoxin neutralizing responses were 
evident in immunized subjects in both age groups at Month 12.  Although there was no clear 
dose-level response pattern, the data suggest that both the antitoxin A –and 
antitoxin B
-specific neutralizing responses were trending higher in the toxoid -only groups 
compared to the toxoid + AlOH groups.  Furthermore, the magnitude of the immune 
response was similar in the 2 age cohorts.
Based on these data, a Phase 2 study  (B5091003) was initiated using a 3 -dose regimen 
(Day s1, 8, and 30) and 2 antigen dose levels (100 and 200 g) of the toxoids alone 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 13reconstituted with sodium chloride diluent.  However, recruitment and vaccinations were 
halted because of the occurrence of 7 cases of Grade 3 injection site redness after Dose 2.  In 
light of this observed tole rability  profile, the decision was made to progress development of 
the AlOH -containing formulation into a second Phase 2 study . This Phase 2 study  
(B5091009) of the AlOH -containing formulation is ongoing to assess the safety, tolerability, 
and immunogenic ity of 2 antigen dose levels (100 and 200 g) and two 3- dose regimens 
(Day s 1, 8, and 30 and Months 0, 1, and 6).  A prespecified interim analy sis of data up to 
Month 7 from this study  demonstrated that the immunogenicit y profile following 3 doses 
administ ered at Months 0, 1, and 6 was superior to that when the doses were administered at 
Days 1, 8, and 30. In addition, the 200- g dose level was more immunogenic than the 
100-g dose level. On this basis, it was decided to progress into Phase 3 development with 
the 200- g dose level administered at Months 0, 1, and 6.
The ongoing Phase 3 efficacy  study  (B5091007) is a placebo -controlled, randomized 
(1:1, vaccine:placebo), observer -blinded, parallel- group stud y in subjects 50 years of age or 
older who have an increased risk of CDI.  In the absence of an accepted immunological 
correlate of protection for CDI, vaccine efficacy  (VE) will be determined by  comparing the 
CDI incidence in recipients of the investigational vaccine with those receiving placebo.
The pre sent study  (B5091008) is a Phase 3, placebo -controlled, randomized, 
observer -blinded study  to evaluate the lot consistency , safet y, tolerability , and 
immunogenicit y of the C difficile vaccine 200- g dose level administered at Months 0, 1, and 
6 in healthy  adults 65 to 85 y ears of age.  The study  seeks to recruit a relatively  healthy  
population in an age category  that is harmonized with the previous Phase 2 study  
(B5091009). The Phase 2 study  provides significant information pertaining to 
immunological and safety  responses, and immunological variability , particularly  1 month 
after Dose 3. This lot -to-lot study  is being conducted to fulfill regulatory  requirements for 
product licensure. Since commercial production of this vaccine will involve multiple 
manuf acturing campaigns and multiple lot productions, it is imperative to demonstrate that 
vaccination from different lots y ields similar responses within an acceptable margin.
Additional information for this compound may  be found in the single reference safet y
document (SRSD), which for this study  is the investigator’s brochure (IB).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 15Subjects withdrawn from the study  after randomization will not be replaced, r egardless of the 
reason for withdrawal.
3.2.Approximate Duration of Subject Participation
Subjects will be followed for 1 month after receipt of their third vaccination.  Therefore, 
individual subjects will participate in the stu dy for approximately  7 months.
3.3.Approximate Duration of the Study
This study  will be completed in approximately  16 months.
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study  is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility  should be reviewed and documented by  an appropriate member of the 
investigator’s stud y team before subjects are included in the study.
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated ICD indicating that the subject has been 
informed of all pertinent aspects of the stud y.
2.Willing and able to comply with scheduled visits, vaccination plan, and other study  
procedures.
3.Health y adults 65 to 85 years of age at enrollment (signing of the I CD) as determined by  
medical assessment, and the clinical judgment of the investigator, to be eligible for the 
study . Subjects with preexisting chronic medical conditions determined to be stable may  
be included.
4.Male subjects or female subjects who are not of childbearing potential (ie, meet at least 1 
of the following criteria):
a.Achieved postmenopausal status, defined as follows: cessation of regular menses for 
at least 12 consecutive months with no alternative patho logical or ph ysiological 
cause; status may  be confirmed with a nonstudy  serum follicle -stimulating hormone 
(FSH) level confirming the postmenopausal state;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ; 
c.Have medic ally confirmed ov arian failure.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 16All other female subjects (including female subjects with tubal ligations) are considered 
to be of childbearing potential.
5.Ability  to be contacted by  telephone during study  participation.
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator, or subjects 
who are Pfizer e mploy ees, including their family  members, directl y involved in the 
conduct of the stud y.
2.Participation in other studies involving investigational drug(s)/vaccine(s) within 28days
prior to study  entry  through conclusion of the study .
3.Previous administration of an investigational C difficile vaccine or C difficile mAb 
therap y.
4.Proven or s uspected prior episode of CDI.
5.Unstable chronic medical condition or disease requiring significant change in therapy  or 
hospitalization for worsening disease within 8 weeks before receipt of investigational 
product.
6.Serious chronic medical disorders, including metastatic malignancy , severe chronic 
obstructive pulmonary  disease (COPD) requiring supplemental oxy gen, end- stage renal 
disease with or without dialy sis, clinicall y unstable cardiac disease, or any  other disorder 
that in the investigator’s opinion precludes the subject from participating in the study .
7.Any bleeding disorder or anticoagulant therapy  that would contraindicate intramuscular 
injection.
8.Any contraindication to vaccination or vaccine components, including previous 
anaph ylactic reaction to any  vaccine or vaccine -related components.
9.Subjects who may be unable to respond to vaccination due to: 
Congenital or acquired immunodeficiency .
Receipt of s ystemic corticosteroids ( 20 mg/day  of prednisone or equivalent) for 
14days within 28 day s of enrollment.
Receipt of chronic s ystemic treatment with other known immunosuppressant 
medications, or radiotherapy, within 6 months of enrollment.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 17Underl ying bone marrow disorde r such as m yelodysplasia, m yeloma, or 
myeloproliferative disorder, treated within the past y ear, or any  history  of bone 
marrow transplant.
Malignancy  that required treatment with chemotherapy  (including the use of 
adjunctive and hormonal therap y), immunotherap y, radiation therap y, or 
antineoplastic target therapies within the past 24 months.
10. Receipt of blood products or immunoglobulins within 6 months before enrollment 
through conclusion of the study .
11. Residence in a nursing home or other long- term care faci lity, or requirement for 
semiskilled nursing care or assisted living.  An ambulatory  subject who lives in an 
autonomous manner in a retirement home or village is eligible for the trial.
12.A known infection with human immunodeficiency  virus (HIV).
13.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavioral or laboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administratio n or 
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the subject inappropriate for entry  into this study .
14. Female subjects of childbearing potential; pregnant female subjects; breastfeeding female 
subjects; fertile male subjects who are unwilling or unable to use a highl y effective 
method of contraception as outlined in this protocol for the duration of the study  and for 
at least 28 day s after the last dose of investigational product.
4.3.Criteria for T emporarily Delaying Vaccine Administration
The following conditions are temporary  or self -limiting and a subject may be vaccinated 
once the condition(s) has/have resolved and no other exclusion criteria are met:
1. Current febrile illness (oral temperature of 38.0 C [100.4 F]) or other acute illness 
within 48 hours prior to investigational product administration.
2.Subject has received seasonal or pandemic influenza vaccine within the previous 14 day s 
or an y other nonstud y vaccine within the previous 28 days be fore investigational product 
administration.
3.If systemic corticosteroids have been administered short term ( 7 day s) for treatment of 
an acute illness, investigational product administration should be delay ed until sy stemic 
corticosteroid use has been disc ontinued for at least 28 day s. Inhaled, intra -
articular/intrabursal, or topical corticosteroids are permitted.
If a subject meets an y delay criteria for vaccination, all study procedures, including blood 
sample collection relating to that visit, should be delay ed until the day  of vaccination.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 184.4.Lifestyle Requirements
4.4.1. Contraception
All fertile male subjects who are, in the opinion of the investigator, sexually active and at risk 
for pregnancy  with their partner(s) must agree to use a highly  effective method o f 
contraception consistently and correctly for the duration of the vaccination period and for at 
least 28 day s after the last dose of investigational product.  The investigator or his or her 
designee, in consultation with the subject, will confirm that the subject has selected an 
appropriate method of contraception for the individual subject and his partner from the 
permitted list of contraception methods (see below) and will confirm that the subject has 
been instructed in its consistent and correct use.  At time points indicated in the 
schedule ofactivities
, the investigator or designee will inform the subject of the need to use 
highl y effective contraception consistently  and correctl y and document the conversation and 
the subject’s affirmation in the subject’s chart (subjects need to affirm their consistent and 
correct use of at least 1 of the selected methods of contraception).  In addition, the 
investigator or designee will instruct the subject to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is know n or suspected in the partner.
Highl y effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal), provided the male 
subject’s female partner plans to remain on the same treatment throughout the entire 
study  and has been using that hormonal contraceptive for an adequate period of time to 
ensure effectiveness.
2.Correctly placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WITH a separate spermicide product (ie, foam, gel, 
film, cream, or suppository ).  For countries where spermicide is not available or condom 
plus spermicide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilizati on with absence of sperm in the postvasectomy  ejaculate.
5.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
6.Female partner who meets th e criteria for nonchildbearing potential, as described below:
Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ;
Have medicall y confirmed ovarian failure; or
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 19Achieved postmenopausal status, defined as follows: cessation of regular mens es for 
at least 12 consecutive months with no alternative pathological or ph ysiological 
cause.
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associat ed with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
4.5.Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the study reference manual (SRM).
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigator site, and contact details for a contact center in the 
event that the investigator site staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .  The contact number can also be used by  investigator 
staff if they  are seeking advice on medical questions or problems; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
establ ished communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.The contact 
number is not intended for use by the subject directly , and if a subject calls that numb er, he 
or she will be directed back to the investigator site.
5.INVESTIGATIONAL PRODUCTS
For the purposes of this study , and per International Council for Harmonisation (I CH) 
guidelines, investigational product is defined as a pharmaceutical form of an activ e 
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an un approved 
indication, or when used to gain further information about an approved use (I CH E6 1.33).
For this study , the investigational products are C difficile vaccine and placebo (saline). Since 
the appearance of these investigational products is not ide ntical, the study  is 
observer -blinded.  The 3 lots of C difficile vaccine will appear identical and all site personnel 
will be blinded to lot allocation.
5.1.Allocation to Investigational Product
Allocation of subjects to vaccine groups will proceed through th e use of an interactive 
response technology  (IRT) sy stem (interactive Web -based response [I WR]) in a 
randomization ratio of 1:1:1:1 to each of the lots and control group.  Study  personnel (either 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 20blinded or unblinded) will be required to enter or select in formation including but not limited 
to the user’s identification (ID) and password, the protocol number, and the subject number.  
They  will then be provided with a randomization number, vaccine assignment, and 
dispensable unit (DU) or container number.  Th e IRT sy stem will provide a confirmation 
report containing the subject number, randomization number, and DU or container number 
assigned.  The confirmation report must be retained by  the unblinded dispenser in the 
unblinded site files.
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system.
5.2.Blinding of Site Personnel
In this observer -blinded study , the study  staff dispensing and administering the vaccine will 
be unblinded, but all other site study  personnel, including the principal investigator and the 
subject, will be blinded.
The principal investigator will assign the responsibility  of the unblinded 
dispensers/administrators to persons who will not participate in the evaluation of any  study 
subject.  To ensure adequate coverage, at least 2 unblinded dispensers/administrators will be 
assigned per site. Members of the study  site staff or clinic pharmacy  should fulfill these 
roles.  Contact between the unblinded dispensers and study  subjec ts should be kept to a 
minimum.  The investigator, study  coordinator, and any  site staff other than the unblinded 
dispensers/administrators must not be allowed to know the investigational product assigned 
to any  study  subject and must not be allowed to see the investigational product container 
contents.
5.3.Blinding of the Sponsor
Those study  team members who are involved in ensuring that protocol requirements for 
investigational product handling, allocation, and administration are fulfilled at the site 
(eg,the unblinded Pfizer clinician [separate from the study  team], clinical research associates 
[CRAs]) will be unblinded for the duration of the study. All other study  team members and 
all laboratory  personnel performing the serology  assay s will remain blinded to vaccine 
assigned/received throughout the study .
5.4.Breaking the Blind
The study  will be subject and investigator blinded.
At the initiation of the study , the investigator site will be instructed on the method for 
breaking the blind.  The method will be an electronic process.  Blinding codes should be 
broken onl y in exceptional circumstances when knowledge of the actual vaccine assignment 
is absolutely  essential for further management of the subject.  Investigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary .  When 
the blinding code is broken, the reason must be fully  documented and entered on the case 
report form (CRF).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 215.5. Subject Compliance
All doses of investigational product will be administered by  the appropriately  designated 
unblinded study  staff at the investigator site.
5.6.Vaccine Supplies
5.6.1. Formulation and Packaging
5.6.1.1. Clostridium difficile Vaccine
The investigational C difficile vaccine is toxoid based. Cdifficile toxin A and toxin B are 
inactivated by a combination of genetic mutations and chemical treatments.  The vaccine is 
provided as a sterile ly ophilized powder in a dosage strength of 200 g/dose (total for 
toxoids A and B).  The vaccine will be reconstituted with AlOH diluent immediately before
use as instructed in the investigational product (IP) manual.  The AlOH diluent is supplied as 
a 1-mg aluminum/mL  (as AlOH) liquid suspension.
Blinded, sealed cartons will contain 1 single -use vial of 
C difficile vaccine lyophilized 
powder for reconstitut ion and 1 single -dose s yringe of AlOH diluent.  The total volume of 
resuspended vaccine to be injected is 0.5 mL per dose.
The investigational products will be provided by  the sponsor to each study  site.  
Investigational product and diluent will be packed and labeled b y Pfizer or its designee as 
investigational product in accordance with current guidelines and applicable local and legal 
regulatory  requirements.  For detailed information on the antigenic components of the 
investigational product, please refe r to the IB.
5.6.1.2. Placebo
The placebo will consist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection, in a 0.5 -mL dose) and will be provided by  the sponsor to each study  site. 
The placebo will be packaged within cartons labeled by Pfizer or its designee in accordance 
with current guidelines and applicable local and legal regulatory  requirements.  Blinded, 
sealed cartons will contain 1 single- dose sy ringe of placebo.  Refer to the IP manual for 
details regarding the preparation an d dispensing of placebo.
5.6.2. Preparation and Dispensing
Refer to the IP manual for instructions on how to prepare the investigational product for 
administration.  I nvestigational product should be prepared and dispensed by  an 
appropriatel y qualified and experi enced unblinded member of the study  staff.
5.6.3. Administration
All injections will be administered in the upper deltoid muscle, preferabl y of the 
nondominant arm, by  the unblinded administrator.  The size of the needle used for 
administration will be based on the subject's weight at the time of enrollment.  Refer to the IP 
manual for additional information.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 22Subjects will receive 1 dose of C difficile vaccine/placebo at Visits 1 (Month 0), 2 (Month 1), 
and 4 (Month 6).
Standard vaccination practices must be obser ved and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of investigational products should be performed b y an appropriately 
qualified, Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the 
study  staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmac ist, or 
medical assistant) as allowed b y local, state, and institutional guidance.
Investigational product administration details will be recorded on the CRF.
5.7. Investigational Product Storage
The investigator or an approved representative, eg, pharmacist, w ill ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements.
Investigational products should be stored in their original contai ners and in accordance with 
the labels.
See the IP manual for storage conditions of the product once reconstituted.
Any storage conditions stated in the SRSD will be superseded b y the storage conditions 
stated on the product label.
The investigational vacc ine, AlOH diluent, and placebo will be shipped at +2 C to +8C to 
each stud y site after required regulatory and legal documents have been received b y the 
sponsor. Upon receipt at the study  site, the products should be immediately  transferred to a 
+2C to +8C temperature -monitored refrigerator for storage.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, r efrigerated, and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions s hould be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability to store or view the minimum/maxi mum 
temperature for all nonworking day s upon return to normal operations.  The operation of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they  are maintained in workin g order.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 23Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery .  The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible.  Dev iations from the storage 
requirements, including any actions taken, must be documented and reported to Pfizer.
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investi gational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
5.8.Investigational Product Accountability
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  All investigational products will be 
accounted for using a drug accountabilit y form/record.
5.8.1. Destruction of Investigational Product Supplies
The sponsor or designee will provide guidance on the destruction o f unused investigational 
product (eg, at the site).  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional p olicy , and any  special instructions provided by  
Pfizer, and all destruction must be adequatel y documented.
5.9. Concomitant Medication(s)
5.9.1. Recording Concomitant Vaccinations and Medications
Subjects will be asked to provide a history  with the name(s) and date(s) for all vaccinations 
received from 28 day s prior to enrollment until completion of the study .  No additional 
concomitant medications will be recorded.
5.9.2. Prohibited Concomitant Vaccinations and Medications
No vaccines other than investigational product should be administered within 28 day s before 
and 28 day s after each study  vaccination (administered at Visits 1, 2, and 4). Exceptions to 
this are the seasonal influenza vaccine and pandemic influenza vaccine, which can be given 
at least 14 day s prior to or 14 days after the administration of investigational product.
Receipt of anticoagulant therap y that would contraindicate intramuscular injection from 
enrollment through the last dose of investigational product.
Receipt of chronic s ystemic treatment with known immunosuppressant medications, or 
radiotherap y, within 6 months before enrollment through conclusion of the study  is 
prohibited.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 24Receipt of s ystemic corticosteroids ( 20 mg/day  of prednisone or equivalent) for 14 day s is 
prohibited from 28 day s prior to enrollment until completion of the study .
Receipt of chemotherap y for a malignancy  (including the use of adjunctive and hormonal 
therapy), immunotherap y, radiation therap y, or antineoplastic target therapies within the past 
24 months until completion of the study .
Receipt of blood products or immunoglobulins within 6 months before enrollment through 
conclusion of the study  is prohibited.
Prophy lactic antipy retics and other pain medication to prevent symptoms associated with 
investigational product administr ation are not permitted.  However, if a subject is taking a 
medication for another condition, even if it may  have antipy retic or pain -relieving properties, 
it should not be withheld prior to study  vaccination.
Receipt of an y other (nonstudy ) investigationa l C difficile vaccine or C difficile mAb therap y 
at an y time prior to or during stud y participation is prohibited.
5.9.3. Permitted Concomitant Medications
The use of antip yretics and other pain medication to treat symptoms associated with 
investigational product administration or ongoing conditions is permitted.
Medication, other than that described as prohibited in Section 5.9.2, required for treatment of 
preexisting stable conditions is permitted.
Inhaled, topical, or localized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permitted.
6.STUDY PROCEDURES
6.1.Study Period
6.1.1. Visit 1: Month 0 –Vaccination 1 (Day 1)
It is anticipated that the procedures below will be condu
cted in a stepwise manner; ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
Obtain written informed consent prior to performing an y protocol -required procedures.
Record the subject’s demograph y (inclu ding date of birth, sex, race, and ethnicity ).  The 
date of birth will be collected to criticall y evaluate the immune response and safet y 
profile b y age.
Conduct a clinical assessment, including review of medical history , to verify  that all 
inclusion crite ria, none of the exclusion criteria, and none of the temporary delay  criteria 
are met ( Section 4). Record medical history  of significance, including the presence of 
chronic medical conditions .  If the clinical assessment indicates that a ph ysical 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 25examination is necessary to comprehensivel y evaluate the subject, perform a physical 
examination and record the findings.
Record nonstud y vaccines as described in Section 5.9.1.
Measure and record the subject’s weigh t and height.
Measure and record the subject’s oral temperature.
Discuss contraceptive use.
Ensure that all inclusion criteria, none of the exclusion criteria, and none of the temporary  
delay  criteria are met ( Section 4).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s randomization number and investigat
ional product blinded carton 
number.
Collect a blood sample of approximately  20 mL for immunogenicit y testing ( Section 7.2).
Unblinded site staff will prepare and administer investigational pr oduct. Investigational 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recorded.  Refer to 
the IP manual under separate cover for further instructio n on this process.
The unblinded vaccine dispenser/administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute rea ctions. Any AEs noted during the observation 
period should be recorded in the CRF.
Record and report AEs and serious adverse events (SAEs) (relative to the time of 
vaccination) as described in Section 8 and the schedule of activities .
Issue a measuring device for measurement of local reactions, and a digital thermometer 
for recording dail y temperatures. Provide instructions on their use and recording.
Explain the requirements for the completion of the e -diary  and assist the subject in 
downloading the stud y application (app) onto the subject’s own device or issue a 
provisioned device (see Section 7.1). Provide instructions and ask the subject to 
complete the e -diary  from Day 1 to Day 7, with Day 1 being the day  of vaccination.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Sche dule an appointment for the subject to return for the next study  visit.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 26Complete the source documents.
Complete the CRF.
Review the e -diary  data online following vaccination to evaluate subject compliance and 
as part of the ongoing safety  review.
6.1.2. Visit 2: Month 1 – Vaccination 2 (28 to 42 Days After Visit 1)
It is anticipated that the procedures below will be conducted in a stepwise manner; ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
Review the su bject’s e -diary  data and follow up on any ongoing local reactions or 
systemic events.
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
Based on clinical evaluation, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8 and the 
schedule ofactivities
.  Review AEs that were ongoing from the previous visit and record 
their stop dates or confir m if they  are still continuing.
Record nonstud y vaccines as described in Section 5.9.1.
Measure and record the subject’s oral temperature.
Discuss contraceptive use.
Ensure that none of the temporary  delay  criteria are met ( Section 4.3).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s investigational product blinded carton number.
Unblinded site staff will prepare and administer investigational product. Investigationa l 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recorded.  Refer to 
the IP manual under separate cover for further instruction on this process.
Theunblinded vaccine dispenser/administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute reactions.  Any AEs noted during the observation 
period should be recorded in the CRF.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 27Ensure the subject has an available measuring device for measurement of local reactions, 
and a digital thermometer for recording dail y temperatures. If required, provide 
instructions on their use.
Confirm that the subject understands the reactogenicity  reporting requirements. Remind 
the subject to complete the e
-diary  from Day 1 to Day 7, with Day 1 being the day  of 
vaccination.
Ask the subject to contact the site staff or investigator immediat ely if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.3. Visit 3: Month 2 (28 to 42 Days After Visit 2)
Contact the subject b y telephone to determine whethe r any AEs or SAEs have occurred 
since the last study  visit.  Record and report findings as described in Section 8and the 
schedule of activities .  Review AEs that were ongoing from the previous visit and record 
their stop dates or confirm if they  are still continuing.
Follow up on an y ongoing local reactions or s ystemic events.
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
Record nonstud y vaccines as described in Section 5.9.1.
Discuss contracepti ve use.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.4. Visit 4: Month 6 –Vaccination 3 (140 to 168 Days After Visit 2)
It is anticipated that the procedures below will be conducted in a stepwise manner; ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 28Review the subject’s e -diary  data and follow up on any ongoing local reactions or 
systemic events.
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
Based on clinical evaluation, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8 and the 
schedule of activities .  Review AEs that were ongoing from the previous visit and record 
their stop dates or confirm if they  are still continuing.
Record nonstud y vaccines and as described in Section 5.9.1.
Measure and record the subject’s oral temperature.
Discuss contraceptive use.
Ensure that none of the temporary  delay  criteria are met ( Section 4.3).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s investigational product blinded carton number.
Unblinded site staff will prepare and administer investigational product. Investigational 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recorded.  Refer to 
the IP manual under separate cover for further instruction on t his process.
The unblinded vaccine dispenser/administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute reactions.  Any  AEs noted during the observation 
period should be recorded in the CRF.
Ensure the subject has an available measuring device for measurement of local reactions, 
and a digital thermometer for recording dail y temperatures. If required, provide 
instruc tions on their use.
Remind the subject to complete the e -diary from Day 1 to Day 7, with Day 1 being the 
day of vaccination.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedul e an appointment for the subject to return for the next study  visit.
Complete the source documents.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 29Complete the CRF.
6.1.5. Visit 5: Month 7 (28 to 42 Days After Visit 4)
Review the subject’s e- diary  data and follow up on any ongoing local reactions or 
systemic events.
Collect the subject’s e -diary  device, if applicable.
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
Based on clinical evaluat
ion, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8 and the 
schedule of activitie s.  Review AEs that were ongoing from the previous visit and record 
their stop dates or confirm if they  are still continuing.
Record nonstud y vaccines as described in Section 5.9.1.
Collect a blood sample of approximately  20 mL for immunogenicit y testing ( Section 7.2).  
Any AEs occurring up to 48 hours after blood draw must be recorded on the CRF.
Complete the source documents.
Complete the CRF.
6.1.6. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section 7.1.1.2 ), systemic event ( Section 7.1.1.3 ), or fever 
(Section 7.1.1.4) is reported in the e- diary  data, a telephone contact should occur to ascertain 
further details and determine whether a site visit is c linically  indicated.
If a suspected Grade 4 local reaction ( Section 7.1.1.2 ), systemic event ( Section 7.1.1.3), or 
fever ( Section 7.1.1.4) is reported, a telephone contact or site visit should occur to confirm 
whether the event meets the criteria for Grade 4.  Only  an investigator or medically  qualified 
person is able 
to classify  a subje ct’s local reaction as Grade 4.
6.2.Subject Withdrawal
Subject eligibility  must be confirmed at each visit by  an appropriate member of the 
investigator's stud y team as described in Section s4and 5.9.2.  If a subject is discontinued 
from vaccination and the subject consents, safety  follow -
up will be conducted for 1 month 
after the last dose of vaccine.
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also the 
Withdrawal From the Study  Due to Adverse Events section) or behavioral reasons, or the 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 30inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given study  site.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  All attempts to contact the subject and information received during contact attempts 
must be docum ented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the subject return for a final visit, if appli cable, 
and follow up with the subject regarding an y unresolved AEs.
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
colle cted.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described.  However, it is anticipate d that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to 
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safet y and well -being of the subjec t.  When a protocol -required test cannot be performed, the 
investigator will document the reason for this and any corrective and preventive actions that 
he or she has taken to ensure that normal processes are adhered to as soon as possible.  The 
study  team will be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of t he study .
7.1.Safety Assessments
Safety  parameters will be assessed as described in the schedule of activities , Section 6, 
Section 8, and below.
A clinical assessment, including medical history
, will be performed on all subjects at Visit 1 
to establish a baseline. Significant medical history  and observations from any  physical 
examination, if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.
Acute reactions within the first 30 minutes after investigational product administration will 
be assessed and documented in the AE CRF.
The safet y parameters also include e -diary  reports of local reactions and s ystemic events that 
occur within 7 day s after investigational product administration.  These prospectively  
collected occurrences of l ocal reactions and s ystemic events are graded as described in 
Section 7.1.1.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 317.1.1. Electronic Diary
Subjects will be required to use an e -diary , based on appropriate technology, and will be 
asked to monitor and record local reactions and s ystemic events from Day  1 to Day  7, with 
Day 1 being the day  of vaccination, following each vaccination. The e -diary  allows 
recording of these assessments only  within a fixed time window, thus providing the accurate 
representation of the subject’s experience at that time.  Data on local reactions and sy stemic 
events reported on the e -diary  will be transferred electronically  to a third
-party  vendor, where 
they will be available for review by  investigators and the Pfi zer clinicians at all times via an 
internet -based portal. E- diary  data review is ongoing during subject e -diary  data -entry  
periods (from Day  1 to Day  7, with Day  1 being the day  of vaccination) via an internet- based 
portal.
At intervals agreed to b y the vendor and Pfizer, these data will be transferred electronicall y 
into Pfizer's database for anal ysis and reporting.  These data do not need to be reported by  the 
investigator in the CRF as AEs.
Investigators (or designee) will be required to review the e-di ary data online at frequent 
intervals as part of the ongoing safet y review.
The investigator or designee should obtain stop dates for an y ongoing local reactions or 
systemic events on the last day  that the e -diary  was completed.  The stop dates should be 
documented in the source documents and the information entered in the CRF.
7.1.1.1. Grading Scales
The grading scales used in this study  to assess local reactions and sy
stemic events as 
described below are derived from the Food and Drug Administration (FDA) Center f or 
Biologics Evaluation and Research (CBER) guidelines on toxicity  grading scales for health y 
adult volunteers enrolled in preventive vaccine clinical trials.58
7.1.1.2. Local Reactions
During the e -diary  reporting period, subjects will be asked to assess redness, swelling, and 
pain at the injection site and to record the s ymptoms in the e -diary .  If a local reaction 
persists beyond the end of the e -diary  period following vaccination, the subject will be 
requested to repo rt that information.  The investigator will enter this additional information in 
the CRF.
Redness and swelling will be measured and recorded in measuring device units (range: 1 to 
21) and then categorized during anal ysis as absent, mild, moderate, or sever e based on the 
grading scale in Table 1.  Measuring device units can be converted to centimeters according 
to the following formula: 1 measuring device unit = 0.5 cm.  Pain at the vaccine injection site 
will be ass essed b y the subject as absent, mild, moderate, or severe according the grading 
scale in 
Table 1.
If a Grade 3 local reaction is reported in the e -diary , the site should contact the subject by  
telephone to ascertai
n further details and determine whether a site visit is clinically  indicated. 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 32Only  an investigator or medically qualified person is able to classify  a subject’s local reaction 
as Grade 4. If a subject experiences a confirmed Grade 4 local reaction, the i nvestigator must 
immediately  notify  the sponsor and, if it is determined to be related to the administration of 
the investigational product, further vaccinations will be discontinued in that subject.  The 
Grade 4 reaction must be recorded in the CRF and is not collected in the e -diary .
Table 1. Local Reaction Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Pain Does not interfere 
with activityInterferes with activity Prevents daily activity Emergency room visit 
or hospitalization for 
severe pain
Erythem a/
Redness2.5cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(21measuring 
device units)Necrosis or exfoliative 
dermatitis 
Induration/
Swelling2.5cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(21measuring 
device units)Necrosis
7.1.1.3. Systemic Events
During the e -diary  reporting period, subjects will be asked to assess vomiting, headache, 
fatigue, new or worsening muscle pain, and new or worsening joint pain and to record the 
symptoms in the e -diary .  The sy mptoms will be assessed by  the subject as absent, mild, 
moderate, or severe according to t he grading scale in Table 2.
If a Grade 3 s ystemic event is reported in the e -diary , a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. Only an 
investigator or medicall y qualified person is able to classify a subject’s s ystemic event as 
Grade 4. If a subject experiences a confirmed Grade 4 systemic event, the investigator must 
immediately  notify  the sponsor and, if it is determined to be relate d to the administration of 
the investigational product, further vaccinations will be discontinued in that subject.   The 
Grade 4 reaction must be recorded in the CRF and is not collected in the e -diary .
Table 2. Systemic Event Gradin g Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Vom iting 1-2 times in 
24hours>2 times in 24 hours Requires IV 
hydrationEmergency room visit or 
hospitalization for 
hypotensive shock
Headache No in terference 
with activitySome interference 
with activitySignificant; prevents 
daily activityEmergency room visit or 
hospitalization for severe 
headache
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 33Table 2. Systemic Event Gradin g Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Fatigue/
TirednessNo interference 
with activitySome interference 
with activitySignificant; prevent s 
daily activityEmergency room visit or 
hospitalization for severe 
fatigue
New or 
worsening 
muscle painNo interference 
with activitySome interference 
with activitySignificant; prevents 
daily activityEmergency room visit or 
hospitalization for severe new 
or worsening muscle pain
New or 
worsening 
joint painNo interference 
with activitySome interference 
with activitySignificant; prevents 
daily activityEmergency room visit or 
hospitalization for severe new 
or worsening joint pain
Abbreviation: IV = intravenous.
7.1.1.4. Fever
In order to record information on fever, a digital thermometer will be given to subjects with 
instructions on how to measure oral temperature at home.  Temperature will be collected in 
the e -diary  in the evening daily  during the e -diary reporting period.  It will also be collected 
at an y time during the e -diary  data collection periods that fever is suspected.  Fever is defined 
as an oral temperature of 38.0C (100.4F).  The highest temperature for each day will be 
recorded in the e -
diary.Temperature will be measured and recorded to 1 decimal place and 
then categorized during analy sis according to the scale shown in T able 3.
If a Grade 3 fever is reported in the e -diary , a telephone contact sh ould occur to ascertain 
further details and determine whether a site visit is clinically  indicated. Only  an investigator 
or medicall y qualified person is able to classify a subject’s fever as Grade 4. If a subject 
experiences a confirmed Grade 4 fever, t he investigator must immediatel y notify  the sponsor 
and, if it is determined to be related to the administration of the investigational product, 
further vaccinations will be discontinued in that subject.
  The Grade 4 reaction must be 
recorded in the CRF.
Table 3. Scale for Fever
Mild (Grade 1) 38.0-38.4C (100.4 -101.1 F)
Moderate (Grade 2) 38.5-38.9C (101.2 -102.0 F)
Severe (Grade 3) 39.0-40.0C (102.1 -104.0 F)
Potentially life threatening (Grade 4) >40.0 C (>104.0 F)
7.2.Immunogen icity Assessments
Serum samples will be obtained for immunogenicity  testing at Visit 1 (Month 0, immediately  
before Dose 1) and Visit 5 (Month 7, 1 month after Dose 3).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 34Both toxin A –and toxin B –specific neutralizing antibody  levels will be measured. 
Appr oximately  20 mL (minimum of 10 mL  and up to 20 mL) of blood will be collected to 
allow for adequate volume required for repeat testing or additional antigen -specific 
immunogenicit y testing to be performed.
Refer to the SRM for details regarding serum sampl e management and storage.
7.3.
Biological Samples
Serum samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory  personnel testing the samples will not know the subject’s identity . 
Samples that remain a fter performing assay s outlined in the protocol may  be stored by  Pfizer. 
Unless a time limitation is required b y local regulations or ethical requirements, the samples 
will be stored for up to 15 y ears after the end of the study  and then destroy ed.  If al lowed b y 
the ICD, stored samples may  be used for additional testing to better understand the immune 
responses to the vaccine(s) under stud y in this protocol, to inform the development of other 
products, and/or for vaccine -related assay  work supporting vacc ine programs.  No testing of 
the subject’s genetic material will be performed.
The subject may request that his or her samples, if still identifiable, be destroy ed at any  time; 
however, an y data already collected from those samples will still be used for t his research.  
The biological samples may be shared with other researchers as long as confidentiality  is 
maintained and no testing of the subject’s genetic material is performed.
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requireme nts for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)nonserious AEs; and (3) exposure to the investigational product under study  during 
pregnancy  or breastfeeding, and occupational exposure.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form  to Pfizer Safety Within 
24Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the investigational 
product under study during 
pregnancy or breastfeeding, and 
occupational exposureAll (regardless of whether associated 
with an AE), except occupational 
exposureExposure during pregnancy, 
exposure via breastfeeding , 
occupational exposure (regardless of 
whether associated with an AE)
All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragra phs.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 35Events listed in the table above that require reporting to Pfizer Safet y on the CT SAE Report 
Form within 24 hours of awareness of the event by  the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the S erious Adverse Events section below).  In addition, the investigator may  be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF .  In general, this wil l include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, mus t be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (e g, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology , and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject. In addition, each study subject will be questioned about the 
occurrence of AEs in a nonleading manner.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 368.1.3. Withdrawal From the Study D ue to Adverse Events (s ee also the Subject 
Withdrawal section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF.
When a subject withdraws from the stud y because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study -related procedure and/or rece iving investigational product), through and including 
Visit 5 (Month 7).
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject durin g the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2.
Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is t he determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 37investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records.
In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source document s and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serio us adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to:
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of und erlying disease;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 38Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medi cation error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires addition al diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in stud y dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therapy ; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
An SAE is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospital ization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 39Medical and s cientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
Medical device complaints may  meet the SAE reporting requirement criteria (see the Medical 
Device Complaint Reporting Requirements sect ion).  An incident is an y malfunction (ie, the 
failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly  or indirectl y, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deteriora tion in their state of health.
A serious injury  that can cause a serious deterioration in state of health can include:
A life -threatening illness, even if temporary  in nature;
A permanent impairment of a bod y function or permanent damage to a body 
structure; 
A condition necessitating medical or surgical intervention to prevent the above 
2bulleted items;
Examples: clinically  relevant increase in the duration of a surgical procedure; a 
condition that requires hospitalization or significant prolongation of existing 
hospitalization;
Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the m anufacturer’s instructions for use;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
8.2.4. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tubercu losis unit).  An emergency  room visit does not necessaril
y constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 40Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clini cal 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a stud y (eg, for a procedure required by the stud y 
protocol);
Optional admission not asso ciated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol an d/or for the individual subject.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the defin ition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 418.3.Severity Assessment
GRADE If require d on the AE page of the CRF, the investigator will use the adjectives 
MILD, MODERATE, SEVERE, or LIFE- THREATENING to describe the 
maximum intensity  of the AE. For purposes of consistency , these intensity  grades 
are defined as follows:
1 MILD Does not interfere with subject's usual function.
2 MODERATE Interferes to some extent with subject's usual function.
3 SEVERE Interferes significantl y with subject's usual function.
4 LIFE -
THREATENINGLife-threatening consequences; urgent intervention indicate d.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serio us unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in pr evious sections, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a subject 
presents with clinical signs/sy mptoms, such LFT results should be managed and followed as 
described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TB ili typicall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory  
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 42sample).  In rare instances, by  the time TBili elevations are detected, AST/AL T values might 
have decreased.  T his occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions .  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values wit hin the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
oPreexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline v alues AND >3 
× ULN; or >8 × ULN (whichever is 
smaller).
oPreexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should retur n to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measur ements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphat ase, and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time o f the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 43travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to ch emicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevatio n defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of inve stigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact with
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or arou nd the time of conception and/or is exposed during 
his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subje ct 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the e xposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 44Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports w ith an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visua l inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, n eonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are r eported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by the sponsor.  Further 
follow -up of birth out comes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved f or use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 45An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report Form 
to Pfizer Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
8.4.4.1. Medication E rrors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength.
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Other examples include, but are not limited to:
The administration of expired investigational product;
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperature 
excursion from the specified storage range, unless it is determine d by the sponsor that 
the investigational product under question is acceptable for use.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the e vent of a medication dosing error, the sponsor should be notified immediately .
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 46Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
8.5.Medical Device Complaint Report ing Requirements
All medical device complaints, regardless of whether the medical device complaint is 
associated with an AE, will be reported by a member of the unblinded site staff as described 
in the I P manual .  This includes potential incidents or malfu nctions associated with the use of 
a medical device product.  An incident or malfunction is an event that might have led to 
death or serious deterioration in health, or if it occurred again might lead to death or serious 
deterioration in health.
Pfizer is to be notified of all medical device complaints within 24 hours of the investigator’s 
awareness of the event.
9. DATA ANALYSIS/STATIS TICAL METHODS
A detailed methodology  for summary  and statistical anal ysis of the data collected in this 
study  will be documented in a statistical analy sis plan (SAP), which will be finalized before 
the start of an y anal yses and will be maintained by  the sponsor. This document may  modify  
the plans outlined in the protocol; however, an y major modifications of the primary  endpoint 
definition and/or its analysis will be reflected both in the amended protocol and in the SAP. 
The SAP amendment will follow the protocol amendment.
9.1.Sample Size Determination
In order to meet the immunogenicity  primary  objective, the study  sample size esti mate is 
based upon the evaluation of lot -to-lot consistency on the toxin A– and toxin B–specific 
neutralizing antibod
y in terms of GMCs, 1 month after the third vaccination (Month 7). A 
2-fold equivalence margin is used for the stud y.Assuming the inhere nt difference for toxin 
A
–and toxin B –specific neutralizing antibod y responses is no more than 0.2 (in logarithmic 
scale) between an y 2lots, and the common standard devi ations for toxin A –and toxin 
B
-specific neutralizing antibodies are 0.899 and 1.485 (natural log value), respectivel y (based 
on the standard deviations for toxin A and toxin B at Month 7 in Study  B5091009), a sample 
size of 263 evaluable subjects per lot will provide an overall 90% power to declare 
equivalence between all 6 comparisons fo r both toxin A and toxin B (see Table 4).
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 47Table 4. Power Analysis (Primary Immunogenicity Endpoint)
Criteria Neutralizing 
AntibodyStandard 
Deviation 
(Log Value)Assu me 
Observed 
Log GMC 
DifferenceNumber o f 
Evaluable 
Subjects per 
LotPoweraOverall Power 
(3Com parisons 
for Each Toxin)
95% CI for 
GMC ratio 
(any 2 lots) 
is betw een 
0.5 and 2.0Toxin A 0.899 0.2 263 >99.99% >99.99%
Toxin B 1.485 0.2 263 96.72% 90.47%
Overall pow er (to meet equivalence for both toxin A and toxin B) 90.47%
a.Using a 2 -fold equivalence margin for GMC ratios a t a 2-sided, 0.05 alpha level.
Assuming a maximum nonevaluable rate of approximately  20%, a total of 1316 subjects need 
to be enrolled to meet the primary  objective, with a randomization ratio of 1:1:1:1 (L ot 1: 
Lot2: Lot 3: placebo).
9.2.Immunogenicity Analysis
The immunogenicit y data will be summarized ac cording to the vaccine group (active vaccine 
and placebo) as received in the evaluable immunogenicity  population, and according to the 
vaccine group as randomized in the modified intent- to-treat (mITT) population.  Subjects 
receiving vaccine who did not fo
llow their randomization assignment will be excluded from 
the evaluable immunogenicity  population.
The C difficile toxin A –and toxin B –specific neutralizing antibody  levels at each blood 
sampling time point will be summarized by  GMCs (any  C difficile toxin A –or toxin 
B-specific neutralizing antibody  level that is below the lower limit of quantitation [LLOQ] 
will be assigned as 0.5 × LLOQ) and the associated 95% confidence intervals (CI s).  The 
GMC will be calculated as the mean of the assay  results after making the logarithm 
transformation and then back transformation to its original scale.  Two (2) -sided 95% CIs 
will be constructed b y back transformation of the CI  for the mean of the logarithmically  
transformed assay  results computed based on the Student’ s t distribution.
Exact 2 -sided 95% CI s will be compiled using the Clopper -Pearson method for an y 
proportions of subjects with C difficile toxin A –or toxin B –specific neutralizing antibody  
level 
cutoff (LLOQ).
9.2.1. Immunogenicity Analysis Population
An evalu able immunogenicity  population and a mITT population will be defined for the 
immunogenicit y anal yses separately .  The evaluable immunogenicit y population will be the 
primary  population for the immunogenicit y analyses.
In general, the evaluable immunogenici ty population will include all subjects who are 
eligible, receive the investigational product to which they  are randomized, have blood drawn 
for assay  testing within the specified time frame, have valid and determinate assay  results for 
either toxin A or t oxin B for the proposed anal ysis, and have no major protocol deviations.  
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 50clinician who is independent of the study  team) and will not be permitted access to the 
randomization assignments until the database is locked and unblinded.
The E- DMC will review safet y data at defined intervals as specified i n the charter. The 
E-DMC may  conduct additional meetings to review safet y data at other time points during 
the study , at its discretion, or at the request of the sponsor. In addition, as determined by  the 
sponsor clinician, the E -DMC may  meet on an ad hoc basis to evaluate any  SAEs related to 
vaccination, or related AEs that may  jeopardize further subject participation, in order to 
determine that the stud y may be continued safel y.
After each meeting, the E -DMC will make recommendations that may  include th e following: 
continue the study  with or without modification; or pause or stop vaccination for safety  or 
other reasons.
The recommendations made b y the E -DMC to alter the conduct of the study  will be 
forwarded to Pfizer for final decision. Pfizer will for ward such decisions, which may  include 
summaries of aggregate anal yses of endpoint events and of safet y data that are not endpoints, 
to regulatory  authorities, as appropriate.
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during stud y conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs are accurate.  The investigator and institution will 
allow Pfizer monitors/auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.  This verification may  also occur 
after stud y completion.
During stud y conduct and/or after stud y completion, the investigator site may be subject to 
review b y the institutional review board (IRB)/ ethics committee (EC), and/or to quality  
assurance audits performed by  Pfizer, or companies working with or on behalf of Pfizer, 
and/or to inspection by  appropriate regulatory  authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study .  Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject's medical records.  The i nvestigator will promptl y provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 5111.DATA HANDLING AND RE CORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorities, w ithout written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that t hey are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring, and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest that the 
data contai ned on the CRFs are true.  An y corrections to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry .
In most cases, the source documents are the hospital or the ph ysician subject chart.  In these 
cases, data collected on the CRFs must match the data in those charts.
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that cle arly identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep re cords, including the identity  of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
ICDs, copies of all CRFs, safety reporting forms, source documents, and detailed records of 
treatment d isposition, and adequate documentation of relevant correspondence (eg, letters, 
meeting minutes, and telephone call reports).  The records should be retained by the 
investigator according to the I CH guidelines, according to local regulations, or as specifi ed in 
the clinical study  agreement (CSA), whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period (eg, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer.
Investigator records must be kept for a minimum of 15 y ears after completion or 
discontinuat ion of the study  or for longer if required by  applicable local regulations.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 52The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Com mittee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, ICDs, and other relevant documents, eg, recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the I RB/EC should be retained in the 
investigator file.  Copies of I RB/EC approvals should be forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immedi ate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and th e Declaration of 
Helsinki.
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any  reports, publications, or other disclosures, except where 
required b y law.
When study  data are compiled for transfer to Pfizer and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced b y numerical codes based on a 
numbering s ystem provided by  Pfizer in order to de -identify  study  subjects.   The investigator 
site will maintain a confidential list of subjects who participated in the study, linking each 
subject’s numerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentia lity and protection of subjects’ personal data consistent 
with applicable privacy  laws.
The informed consent documents and an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, includin g 
applicable privacy  laws.
The I CDs used during the informed consent process and any  subject recruitment materials 
must be reviewed and approved b y Pfizer, approved by the IRB/EC before use, and available 
for inspection.
The investigator must ensure that e ach study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 53The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before a ny study -specific activity  is performed.  The investigator 
will retain the original of each subject's signed consent document.
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be infor med immediately .
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP tha t the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in All Participating Countries
End of trial in all participating countries is defined as database lock.
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC, or investigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
Cdifficile vaccine at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 28 day s.  As directed by  Pfizer, all study materials must be collected 
and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical trial results through posting the 
results of s tudies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfi zer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials. gov for Pfizer- sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 54Pfizer product, regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary  completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes o
f final collection of data for the primary  outcome, whether the clinical study  
concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosu re Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www .clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the 
principal investigator (PI) of the results of the study based on information collected or 
generated b y the PI, wh ether or not the results are favorable to the Pfizer product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the investigator will provide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study (collectively, “publication”) 
before it is submitted or otherwise disclosed.
The investigator will provide any  publication to Pfizer at least 30 day s before it is submitted 
for publication or otherwise disclosed.  If an y patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 day s.
The investigator will, on request, remove an y previously  undisclosed co nfidential 
information before disclosure, except for an y study -or Pfizer product -related information 
necessary  to the appropriate scientific presentation or understanding of the study  results.
If the stud
y is part of a multicenter study, the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
by the PI will reference that primary  publication.  However, if a joint manuscript has not 
been submitted for publication w ithin 12 months of completion or termination of the study  at 
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 55all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this section.
For all publications relating to the stud y, the institution will comply with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, t he defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 5616.REFERENCES
1. Guerrant RL , Hughes JM, L ima NL, Crane J. Diarrhea in developed and developing 
countries: magnitude, special settings, and etiologies. Rev Infe ct Dis . 
1990;12(suppl 1):S41 -S50.
2. Kelly  CP, Pothoulakis C, L aMont JT. Clostridium difficile colitis. N Engl J Med. 
1994;330(4):257 -262.
3. Kyne L, Kell y CP. Prospects for a vaccine for Clostridium difficile . BioDrugs . 
1998;10(3):173 -
181.
4. McFarland LV. Epidemi ology  of infectious and iatrogenic nosocomial diarrhea in a 
cohort of general medicine patients. Am J Infect Control . 1995;23(5):295 -305.
5. Magill SS, Edwards JR, Bamberg W, et al; for the Emerging Infections Program 
Healthcare -Associated Infections and Anti microbial Use Prevalence Survey  Team. 
Multistate point -prevalence survey  of health care –associated infections. N Engl J Med. 
2014;370(13):1198 -1208.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium 
difficile infection in adults: 2010 update by  the Society  for Healthcare Epidemiology  of 
America (SHEA) and the I nfectious Diseases Society  of America (IDSA). Infect 
Control Hosp Epidemiol. 2010;31(5):431 -455.
7. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile -associated disease: 
old therapies and new strategies. Lancet Infect Dis . 2005;5(9):549 -557.
8. Kuehne SA, Collery  MM, Kelly  ML, Cartman ST, Cockayne A, Minton NP. 
Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium 
difficile strain. J Infect Dis. 2014;209(1):83 -86.
9. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in 
disease. Clin Microbiol Rev . 2005;18(2):247 -263.
10. Sunenshine RH, McDonald L C. Clostridium difficile -associated disease: new challenges 
from a n established pathogen. Cleve Clin J Med . 2006;73(2):187-197.
11. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 
2015;372(16):1539 -1548.
12. Bartlett JG. Antibiotic -associated diarrhea. N Engl J Med. 2002;346(5):334 -339.
13. Mayo Clinic Staff. D iseases & conditions: C. difficile infection. 
http://www.may oclinic.org/diseases- conditions/c -difficile/basics/sy mptoms/con -
20029664.  16 July  2013.  Accessed 27 February  2016.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 5714. Bauer MP, Notermans DW, van Benthem BHB, et al; for the ECDI S Study Group. 
Clostridium difficile infection in Europe: a hospital- based survey . Lancet . 
2011;377(9759):63 -
73.
15. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile
infection. Clin Infect Dis. 2008;46(suppl 1):S12- S18.
16. Pepin J, Valiquette L . Cossette B. Mortalit y attributable to nosocomial Clostridium 
difficile –associated disease during an epidemic caused by  a hy pervirulent strain in 
Quebec. Can Med Assoc J . 2005;173(9):1037
-1041.
17. Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in 
long-term care facilities: a review. J Am Geriatr Soc . 2010;58(8):1556 -1564.
18. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin 
Infect Dis . 2008;46(suppl 1):S32 -S42.
19. Louie TJ, Miller MA, Mullane KM, et al; for the OPT -80-003 Clinical Study  Group. 
Fidaxomicin versus vancomy cin for 
Clostridium difficile infection. N Engl J Med.
2011;364(5):422 -431.
20. Kyne L, Warny  M, Qamar A, Kelly  CP. Association between antibody  response to toxin 
A and protection against recurrent Clostridium difficile diarrhoea. Lancet . 
2001;357(9251):189- 193.
21. Debast SB, Bauer MP, Kuijper EJ; on behalf of the Committee. European Society  of 
Clinical Microbiology  and I nfectious Diseases: update of the treatment guidance 
document for Clost ridium difficile infection. Clin Microbiol Infect. 2014; 
20(suppl 2):1-26.
22. Ricciardi R, Rothenberger DA, Madoff RD, Baxter N. Increasing prevalence and 
severit y of Clostridium difficile colitis in hospitalized patients in the United States. Arch 
Surg. 2007;142(7):624-131.
23. Khanna S, Pardi DS. The growing incidence and severit y of Clostridium difficile
infection in inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol.
2010;4(4):409 -416.
24. Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with 
development of severe -complicated Clostridium difficile infection. Clin Gastroenterol 
Hepatol. 2013;11(11):1466 -1471.
25. Hensgens MPM, Goorhuis A, Dekkers OM, van Benthem GHB, Kuijper EJ. All- cause 
and disease -specific mortality  in hospitalize d patients with Clostridium difficile
infection: a multicenter cohort study . Clin Infect Dis. 2013;56(8):1108 - 1116.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 5826. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbay a A, Haider S. Clinical and 
economic burden of Clostridium difficile infection in Europe: a s ystematic review of 
healthcare -facility -acquired infection. J Hosp Infect . 2012;81(1):1 -14.
27. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the 
United States. N Engl J Med. 2015;372(9):825 -834.
28. Dubberke E. Clostridium difficile infection: the scope of the problem. J Hosp Med. 
2012;7(suppl 3):S1- S4.
29. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare sy stem. Clin 
Infect Dis . 2012;55(suppl 2):S88 -S92.
30. Gerding DN, Lessa FC. The epidemiology  of Clostri dium difficile infection inside and 
outside health care institutions. Infect Dis Clin North Am . 2015;29(1):37 -50.
31. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi -institutional 
outbreak of Clostridium difficile –associated diarrhea with hig h morbidit y and mortality . 
N Engl J Med
. 2005;353(23):2442-2449.
32. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene–variant strain 
of Clostridium difficile . N Engl J Med. 2005;353(23):2433-2441.
33. Pepin J, Valiquette L , Alary  ME, et al. Clostridium difficile -associated diarrhea in a 
region of Quebec from 1991 to 2003: a changing pattern of disease severity . Can Med 
Assoc J. 
2004;171(5):466-472.
34. Gerding DN. Clindam ycin, cephalosporins, fluoroquinolones, and Clostridium difficile –
associated di arrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 
2004;38(5):646 -648.
35. Kyne L, Farrell RJ, Kelly  CP. Clostridium difficile . Gastroenterol Clin North Am . 2001; 
30(3):753
-777.
36. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside 
and outside the box. Clin Infect Dis. 2010;51(11):1306-1313.
37. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for 
Clostridium difficile infection in adults and children: 2017 update b y the Infectious 
Diseases S ociet y of America (IDSA) and Societ y for Healthcare Epidemiology  of 
America (SHEA). Clin Infect Dis. 2018;66(7):987 -994.
38. Mattila E, Uusitalo -Seppala R, Wuorela M, et al. Fecal transplantation, through 
colonoscop y, is effective therap y for recurrent Clostri dium difficile infection. 
Gastroenterology . 2012;142(3):490 -496.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 5939. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for 
recurrent Clostridium difficile . N Engl J Med. 2013;368(5):407-415.
40. Anony mous. Guidance for industry : enforcemen t policy  regarding investigational new 
drug requirements for use of fecal microbiota for transplantation to treat Clostridium 
difficile infection not responsive to standard therapies. US Food and Drug 
Administration (FDA), US Department of Health and Human Services. 
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformati
on/Guidances/Vaccines/ucm361379.htm.  July  2013. Accessed 27 February  2016.
41. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium difficile
infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol.
2014;35(6):628 -
645.
42. Kyne L, Warny  M, Qamar A, Kelly  CP. As ymptomatic carriage of Clostridium difficile
and serum levels of IgG antibody  against toxin A. N Engl J Med. 2000;342(6):3 90-397.
43. Warny  M, Vaerman JP, Avesani V, Delmee M. Human antibody  response to 
Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun.
1994;62(2):384 -
389.
44. Gupta SB, Mehta V, Dubberke ER, et al. Antibodies to toxin B are prote ctive against 
Clostridium difficile infection recurrence. Clin Infect Dis . 2016;63(6):730 -734.
45. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed 
against toxins A and B prevent Clostridium difficile -induced mortality  in hamsters. 
Infect Immun. 2006;74(11):6339 -6347.
46. Torres JF, Ly erly DM, Hill JE, Monath TP. Evaluation of formalin -inactivated 
Clostridium difficile vaccines administered b y parenteral and mucosal routes of 
immunization in hamsters. Infect Immun . 1995;63(12):4619-4627.
47. Giannasca PJ, Zhang ZX, Lei WD, et al. Serum antitoxin antibodies mediate sy stemic 
and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 
1999;67(2):527 -538.
48. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against 
Clostridium difficile toxins. N Engl J Med. 2010;362(3):197 -205.
49. Merck & Co., Inc. Pivotal Phase 3 studies of bezlotoxumab, Merck’s investigational 
antitoxin to prevent Clostridium difficile infection recurrence, met primary  endpoint. 
http://www.mercknewsroom.com/news -release/research -and-development -
news/pivotal -phase -
3-studies -bezlotoxumab -mercks -investigation.  September 2015.  
Accessed 24 March 2016.
50. Greenberg RN, Marbury  TC, Foglia G, Warny  M.  Phase I dose finding studies of an 
adjuvanted Clostridium difficile toxoid vaccine. Vaccine . 2012;30(13):2245-2249.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 6051. Kotloff KL, Wasserman SS, L osonsky  GA, et al.  Safety  and immunogenicity  of 
increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.  
Infect Imm un. 2001;69(2):988 - 995.
52. Aboudola S, Kotloff KL, Ky ne L, et al.  Clostridium difficile vaccine and serum 
immunoglobulin G antibody  response to toxin A.  Infect Immun . 2003;71(3):1608-1610.
53. Ghose C, Kelly  CP. The prospect for vaccines to prevent Clostridium difficile infection.  
Infect Dis Clin North Am . 2015;29(1):145 -162.
54. Anony mous. Study  of candidate Clostridium difficile toxoid vaccine (Cdiffense) in 
subjects at risk for C difficile infection. Sanofi Pasteur Inc. ClinicalTrials.gov. 
https://www.clinicaltr ials.gov/ct2/show/[STUDY_ID_REMOVED].   December 2015. Accessed 
27February  2016.
55. Tian JH, Fuhrmann SR, Kluepfel -Stahl S, Carman RJ, Ellingsworth L , Flyer DC.  A 
novel fusion protein containing the receptor binding domains of C. difficile toxin A and 
toxin B elic its protective immunity  against lethal toxin and spore challenge in 
preclinical efficacy  models.  Vaccine . 2012;30(28):4249-4258.
56. Anony mous. Dose -confirmation, immunogenicity  and safet y stud y of the Clostridium 
difficile vaccine candidate VLA84 in healthy  adults aged 50 y ears and older. Phase II 
study . Valneva Austria GmbH. ClinicalTrials.gov.  
https://www.clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED].   October 2015.  Accessed 
27February  2016.
57. Sheldon E, Kitchin N, Peng Y, et al. A phase 1, placebo -controlled, randomized study  
of the safet y, tolerability , and immunogenicit y of a Clostridium difficile vaccine 
administered with or without aluminum hy droxide in healthy  adults. 
Vaccine.
2016;34(18):2082 -2091.
58. Food and Drug Administration (FDA) Center for Biologics E valuation and Research 
(CBER). Guidance for Industry : Toxicity  Grading Scale for Health y Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Rockville, MD: 
CBER; September 2007.
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 61Appendix 1.Abbreviations
The following is a list of abbrevia tions that may  be used in the protocol.
Abbreviation Term
AE adverse event
AlOH aluminum hy droxide
ALT alanine aminotransferase
AST aspartate aminotransferase
CBER Center for Biologics Evaluation and Research
CDI Clostridium difficile infection
CI confidence interval
CK creatine kinase
COPD chronic obstructive pulmonary  disease
CRA clinical research associate
CRF case report form
CSA clinical study  agreement
CT clinical trial 
DILI drug-induced liver injury
DU dispensable unit
EC ethics comm ittee
e-diary electronic diary
E-DMC external data monitoring committee
EDP exposure during pregnancy
ELISA enzy me-linked immunosorbent assay
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States )
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMC geometric mean concentration
GMFR geometric mean fold rise
HIV human immunodeficiency virus 
IB investigator's brochure
ICD informed consent document 
ICH International Council for Harmonisation
ID identification
IDSA Infectious Diseases Society  of America
IgG immunoglobulin G
IND investigational new drug application
INR international normalized ratio
IP investigational product
PF-06425090 ( Clostridium difficile Vaccine)
B5091008
Final Protocol Amendment 1, 08 November 2018
PFIZER CONFIDENTIAL
Page 62Abbreviation Term
IRB institutional review board
IRT interactive response technology
IUD intrauterine device
IWR interactive Web -based response
LFT liver function test
LLOQ lower limit of quantitation
mAb monoclonal antibody
MedDRA Medical Dictionary  for Regulatory  Activities
mITT modified intent -to-treat
N/A not applicable
PCD primary  completion date
PFGE pulsed-field gel electrophoresis
PI principal investigator 
PT prothrombin time 
RCDC reverse cumulative distribution curves
SAE serious adverse event
SAP statistical analy sis plan
SRM study  reference manual
SRSD single reference safet y document
TBili total bilirubin
TcdA Clostridium difficile toxin A
TcdB Clostridium difficile toxin B
ULN upper limit of normal
US United States
VE vaccine efficacy
'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	



	


	
'RFXPHQW 7LWOH !" #$#%&#"" '&'#()* '# &+ &$
")' '%,'-%# +",% % "#%#)% -. %-%#" &)")%-')((,#/ ))%-#."#%&)'),(')..))" +) ) "%-',"%0%#
- &#./ 
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
	!$
$	
	0676 .4

	8$
$	
	6	60 .4
PPD
PPD